BR112022010349A2 - Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma - Google Patents

Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma

Info

Publication number
BR112022010349A2
BR112022010349A2 BR112022010349A BR112022010349A BR112022010349A2 BR 112022010349 A2 BR112022010349 A2 BR 112022010349A2 BR 112022010349 A BR112022010349 A BR 112022010349A BR 112022010349 A BR112022010349 A BR 112022010349A BR 112022010349 A2 BR112022010349 A2 BR 112022010349A2
Authority
BR
Brazil
Prior art keywords
ubiquitin
pathway
proteosoma
btk
bifunctional compounds
Prior art date
Application number
BR112022010349A
Other languages
English (en)
Inventor
T Sands Arthur
Kelly Aileen
Original Assignee
Nurix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nurix Therapeutics Inc filed Critical Nurix Therapeutics Inc
Publication of BR112022010349A2 publication Critical patent/BR112022010349A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)

Abstract

COMPOSTOS BIFUNCIONAIS PARA DEGRADAR BTK POR MEIO DE VIA DA UBIQUITINA-PROTEOSSOMA. A presente invenção refere-se a compostos úteis para degradar BTK através de uma via da ubiquitina-proteossoma. A descrição também fornece composições farmaceuticamente aceitáveis compreendendo os referidos compostos e métodos de uso das composições no tratamento de várias doenças, condições ou distúrbios.
BR112022010349A 2019-12-04 2020-12-03 Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma BR112022010349A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943720P 2019-12-04 2019-12-04
US202063010524P 2020-04-15 2020-04-15
PCT/US2020/063176 WO2021113557A1 (en) 2019-12-04 2020-12-03 Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Publications (1)

Publication Number Publication Date
BR112022010349A2 true BR112022010349A2 (pt) 2022-08-16

Family

ID=74004152

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010349A BR112022010349A2 (pt) 2019-12-04 2020-12-03 Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma

Country Status (11)

Country Link
US (2) US11820781B2 (pt)
EP (1) EP4069237A1 (pt)
JP (1) JP2023504147A (pt)
KR (1) KR20220112273A (pt)
CN (1) CN115003304A (pt)
AU (1) AU2020397920A1 (pt)
BR (1) BR112022010349A2 (pt)
CA (1) CA3160713A1 (pt)
IL (1) IL293797A (pt)
MX (1) MX2022006672A (pt)
WO (1) WO2021113557A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023024103A2 (pt) 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos
CN113677668A (zh) 2019-01-30 2021-11-19 蒙特利诺治疗公司 用于雄激素受体靶向泛素化的双官能化合物和方法
CN114364667A (zh) 2019-04-09 2022-04-15 紐力克斯治疗公司 用于Cbl-b抑制的3-取代哌啶类化合物以及Cbl-b抑制剂与癌症疫苗和/或溶瘤病毒联合的用途
MX2021013751A (es) 2019-05-17 2022-01-26 Nurix Therapeutics Inc Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos.
CN115003304A (zh) 2019-12-04 2022-09-02 纽力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
CA3169011A1 (en) 2020-02-25 2021-09-02 Xiaobao Yang Glutarimide skeleton-based compounds and uses thereof
JP2023525047A (ja) 2020-05-06 2023-06-14 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2022272053A1 (en) * 2021-06-25 2022-12-29 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith
WO2023274390A1 (zh) * 2021-07-01 2023-01-05 杭州和正医药有限公司 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用
CN118019538A (zh) 2021-07-14 2024-05-10 纽力克斯治疗公司 用于降解BTK并具有降低的IMiD活性的双官能化合物
CN118019539A (zh) 2021-07-23 2024-05-10 纽力克斯治疗公司 用于降解BTK并具有增强的IMiD活性的双官能化合物
WO2023009709A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Pyrazolo piperazines as jak2 inhibitors
WO2023039081A2 (en) * 2021-09-08 2023-03-16 Memorial Sloan-Kettering Cancer Center Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors
WO2023039603A2 (en) * 2021-09-13 2023-03-16 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
WO2023059582A1 (en) * 2021-10-04 2023-04-13 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
IL312357A (en) * 2021-10-26 2024-06-01 Nurix Therapeutics Inc Piperidinylpyrazine-carboxamide compounds for the treatment and prevention of cancer and to restore BTK
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023088406A1 (zh) * 2021-11-18 2023-05-25 正大天晴药业集团股份有限公司 稠合酰亚胺类衍生物
WO2023088477A1 (zh) * 2021-11-22 2023-05-25 杭州和正医药有限公司 一种可降解btk激酶的多功能化合物、组合物及应用
WO2023239629A1 (en) 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2
CN117384161A (zh) * 2022-07-04 2024-01-12 华东理工大学 靶向降解cdk蛋白的化合物及其应用
WO2024026256A1 (en) * 2022-07-25 2024-02-01 Celgene Corporation Substituted imidazopyrazine compounds as ligand directed degraders of irak3
WO2024102970A1 (en) * 2022-11-11 2024-05-16 Kronos Bio, Inc. Compounds for modulating syk activity and e3 ubiquitin ligase activity

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099388A2 (en) 2003-03-05 2004-11-18 Proteologics, Inc. Cbl-b polypeptides, complexes and related methods
JP5984324B2 (ja) 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
WO2008033403A2 (en) 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Agents and methods to elicit anti-tumor immune response
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
ES2420846T3 (es) 2008-02-05 2013-08-27 F. Hoffmann-La Roche Ag Nuevas piridinonas y piridazinonas
CN110818724B (zh) 2010-05-07 2020-11-13 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2471548A1 (de) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
US20130110678A1 (en) 2011-11-02 2013-05-02 Apple Inc. Purchasing a product in a store using a mobile device
BR112014010460A2 (pt) 2011-11-03 2017-04-18 Hoffmann La Roche composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US9499548B2 (en) 2012-09-13 2016-11-22 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
US9382246B2 (en) * 2013-12-05 2016-07-05 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
CN107709315A (zh) 2015-06-02 2018-02-16 药品循环有限责任公司 布鲁顿酪氨酸激酶的抑制剂
ES2793014T3 (es) 2015-07-17 2020-11-12 Takeda Pharmaceuticals Co Derivados de oxadiazol útiles como inhibidores de HDAC
EP3532607B1 (en) 2016-10-26 2024-01-31 Iovance Biotherapeutics, Inc. Restimulation of cryopreserved tumor infiltrating lymphocytes
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
AU2017363252B2 (en) * 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US20220324835A1 (en) 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
BR122023024103A2 (pt) 2018-10-15 2024-02-20 Nurix Therapeutics, Inc. Compostos bifuncionais para degradação de btk por meio da via de proteossoma de ubiquitina, composição farmacêutica compreendendo os mesmos, e seus usos
US20220143195A1 (en) 2019-02-13 2022-05-12 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CN114364667A (zh) 2019-04-09 2022-04-15 紐力克斯治疗公司 用于Cbl-b抑制的3-取代哌啶类化合物以及Cbl-b抑制剂与癌症疫苗和/或溶瘤病毒联合的用途
MX2021013751A (es) 2019-05-17 2022-01-26 Nurix Therapeutics Inc Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos.
KR20220026581A (ko) 2019-06-26 2022-03-04 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제를 위한 치환된 벤질-트리아졸 화합물, 및 이의 추가의 용도
US20220387395A1 (en) 2019-07-30 2022-12-08 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
CA3152281A1 (en) 2019-09-24 2021-04-01 Arthur T. Sands Cbl inhibitors and compositions for expansion of immune cells
EP4055019A1 (en) 2019-11-08 2022-09-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CN115003304A (zh) 2019-12-04 2022-09-02 纽力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
CN118019538A (zh) 2021-07-14 2024-05-10 纽力克斯治疗公司 用于降解BTK并具有降低的IMiD活性的双官能化合物
CN118019539A (zh) 2021-07-23 2024-05-10 纽力克斯治疗公司 用于降解BTK并具有增强的IMiD活性的双官能化合物
IL312357A (en) 2021-10-26 2024-06-01 Nurix Therapeutics Inc Piperidinylpyrazine-carboxamide compounds for the treatment and prevention of cancer and to restore BTK

Also Published As

Publication number Publication date
WO2021113557A1 (en) 2021-06-10
MX2022006672A (es) 2022-08-08
EP4069237A1 (en) 2022-10-12
US20230227471A1 (en) 2023-07-20
CA3160713A1 (en) 2021-06-10
AU2020397920A1 (en) 2022-06-16
US20210198280A1 (en) 2021-07-01
US11820781B2 (en) 2023-11-21
JP2023504147A (ja) 2023-02-01
IL293797A (en) 2022-08-01
KR20220112273A (ko) 2022-08-10
CN115003304A (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
MX2021004191A (es) Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
PH12020551425A1 (en) Rimegepant for cgrp related disorders
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CR8778A (es) Revestimientos de azucar y metodos para estos
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
BR112022001161A2 (pt) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
MX2021004566A (es) Compuestos terapeuticos.
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
BR112023018472A2 (pt) Composições de psilocibina, métodos de produção e métodos de uso das mesmas
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
MX2022000712A (es) Moduladores de nlrp3.
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
BR112021014566A2 (pt) Moduladores de gpr35
PH12020550104A1 (en) Salts of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023025072-9 PROTOCOLO 870230105092 EM 29/11/2023 16:53.